CMPC Tissue commissions Metso to supply tissue production line for its mill in Santiago, Chile; startup scheduled during 2013

HELSINKI , October 31, 2011 (press release) – Metso will supply a complete tissue production line to CMPC Tissue S.A. of Santiago, Chile. The tissue line will be installed at CMPC’s Talagante mill in Chile. The line will be started up during 2013. The value of the order will not be disclosed. This kind of production line is typically valued at EUR 20-30 million, depending on the scope of the delivery and the production output.

Metso’s delivery will comprise a complete tissue production line with stock preparation equipment and a tissue machine including a headbox, a Yankee cylinder, a hood, a dust management system and a reel. The production line will be optimized to enhance final product quality and save energy.

The delivery will also contain an extensive automation package including a process automation system for machine, process and drive controls as well as a quality control system.

The new production line will produce high-quality facial, toilet and towel grades. The raw material for the new line will be virgin and DIP pulp.

The main part of the order is included in Paper and Fiber Technology’s third quarter 2011 orders received and the automation package in Energy and Environmental Technology’s third quarter 2011 orders received.

CMPC Tissue S.A. is part of the larger pulp and paper group Empresas CMPC, and is a leading tissue products supplier in Latin America with industrial operations in 8 countries of that region.

Metso is a global supplier of sustainable technology and services for mining, construction, power generation, automation, recycling and the pulp and paper industries. We have about 29,000 employees in more than 50 countries.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.